Saxenda (liraglutide) is a GLP-1 agonist injection pen medication used to support long-term weight loss in adults with obesity, adults with overweight and weight-related health issues, and certain ...

More than half of people prescribed weight-loss drugs Saxenda and Wegovy over the past decade ended their treatment too early to realize meaningful health benefits, according to a study by a major U.S ...

The review comes after three people reported thoughts of self-harm or suicide. Regulators in Europe have launched a review after three people in Iceland experienced thoughts of suicide or self-harm ...

While Novo Nordisk A/S NVO is still struggling with a shortage of its popular obesity medicine Wegovy (semaglutide), another weight loss drug has also made it to the FDA's list of drugs facing a ...

Research suggests 10% of people on GLP-1s have some nutritional deficiency six months on.

The weight-loss drug liraglutide helped obese children lower their BMI and reach a healthier weight, researchers report. The findings, published Tuesday in the New England Journal of Medicine and ...

LOS ANGELES, CALIFORNIA - APRIL 17: Boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California. Ozempic was originally approved by the FDA to treat ...

The South Korean government said Monday it plans to tighten regulations on the misuse of medications such as Wegovy and ...

The NC State Health Plan’s coverage of popular obesity medications ends in one week, affecting thousands of public employees using them. Some may be looking for alternatives to these medications.

Credit: FDA. Increased demand for the drug has resulted in supply interruptions. Saxenda (liraglutide) may be in short supply through the end of 2023, according to the Food and Drug Administration’s ...

In the ever-evolving symphony of weight loss medications, Saxenda (Liraglutide) has long taken center stage as a virtuoso in pharmaceutical solutions for shedding unwanted pounds. Yet, the search for ...